Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens.

Antibodies, Bacterial / blood Antigens, Bacterial / immunology Bacterial Outer Membrane Proteins / immunology Bordetella pertussis / immunology Humans Pertussis Toxin / immunology Reproducibility of Results Serologic Tests / methods Virulence Factors, Bordetella / immunology
Assay validation Luminex Multiplex serology Pertussis SAS

Journal

Biologicals : journal of the International Association of Biological Standardization
ISSN: 1095-8320
Titre abrégé: Biologicals
Pays: England
ID NLM: 9004494

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 24 01 2018
revised: 24 10 2018
accepted: 02 11 2018
pubmed: 22 11 2018
medline: 30 4 2019
entrez: 22 11 2018
Statut: ppublish

Résumé

Despite wide spread vaccination, the public health burden of pertussis remains substantial. Current acellular pertussis vaccines comprise upto five Bordetella pertussis (Bp) antigens. Performing an ELISA to quantify antibody for each antigen is laborious and challenging to apply to pediatric samples where serum volume may be limited. We developed a microsphere based multiplex antibody capture assay (MMACA) to quantify antibodies to five pertussis antigens; pertussis toxin, pertactin, filamentous hemagglutinin and fimbrial antigens 2/3, and adenylate cyclase toxin in a single reaction (5-plex) with a calibrated reference standard, QC reagents and SAS

Identifiants

DOI: 10.1016/j.biologicals.2018.11.001 PMID: 30458978 PMC: PMC8864582
pubmed: 30458978
pii: S1045-1056(18)30371-3
doi: 10.1016/j.biologicals.2018.11.001
pmc: PMC8864582
mid: NIHMS1778589
pii:
doi:

Substances chimiques

Antibodies, Bacterial 0
Antigens, Bacterial 0
Bacterial Outer Membrane Proteins 0
Virulence Factors, Bordetella 0
pertactin 63GD90PP8X
Pertussis Toxin EC 2.4.2.31

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-20

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Published by Elsevier Ltd.

Références

J Clin Microbiol. 2010 Dec;48(12):4459-63
pubmed: 20943873
J Mol Diagn. 2007 Feb;9(1):80-8
pubmed: 17251339
J Immunol Methods. 2005 Jan;296(1-2):135-47
pubmed: 15680158
Expert Rev Vaccines. 2014 Oct;13(10):1183-90
pubmed: 25096058
Clin Microbiol Rev. 2005 Apr;18(2):326-82
pubmed: 15831828
Am J Clin Pathol. 2002 Apr;117(4):589-96
pubmed: 11939734
PLoS Pathog. 2006 Jul;2(7):e65
pubmed: 16839199
Clin Infect Dis. 2013 May;56(10):1458-65
pubmed: 23386629
Emerg Infect Dis. 2002 Oct;8(10):1103-10
pubmed: 12396924
J Infect Dis. 2000 Jun;181(6):2087-91
pubmed: 10837200
J Immunol Methods. 2008 Apr 20;333(1-2):89-106
pubmed: 18304568
Pathog Dis. 2015 Nov;73(8):ftv057
pubmed: 26253079
Lancet Infect Dis. 2017 Sep;17(9):974-980
pubmed: 28623146
Pediatrics. 2015 Feb;135(2):331-43
pubmed: 25560446
Pathog Dis. 2015 Oct;73(7):
pubmed: 26208655
Clin Vaccine Immunol. 2008 May;15(5):744-9
pubmed: 18321880
Vaccine. 2006 Jun 12;24(24):5093-107
pubmed: 16838413
Clin Vaccine Immunol. 2008 Aug;15(8):1188-93
pubmed: 18550729
Pediatrics. 2015 Oct;136(4):635-41
pubmed: 26347437
MMWR Morb Mortal Wkly Rep. 2016 Nov 25;65(46):1306-1321
pubmed: 27880744
Clin Vaccine Immunol. 2012 Jan;19(1):64-72
pubmed: 22116688
Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S288-91
pubmed: 11709761
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):575-6
pubmed: 24381159
Clin Infect Dis. 2014 Mar;58(6):830-3
pubmed: 24363332
Clin Vaccine Immunol. 2011 Apr;18(4):595-603
pubmed: 21325488
Biologicals. 2013 Mar;41(2):98-103
pubmed: 23266055
Clin Vaccine Immunol. 2012 Oct;19(10):1609-17
pubmed: 22875603
Clin Vaccine Immunol. 2006 Feb;13(2):266-70
pubmed: 16467336
J Immunol Methods. 2008 Jun 1;335(1-2):79-89
pubmed: 18407287
J Pharm Biomed Anal. 2000 Jan;21(6):1249-73
pubmed: 10708409
Clin Diagn Lab Immunol. 2002 Jul;9(4):872-6
pubmed: 12093688
Faraday Discuss. 2006;132:303-8; discussion 309-19
pubmed: 16833125
J Clin Microbiol. 2000 Feb;38(2):800-6
pubmed: 10655388
Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69
pubmed: 16085914
Pediatr Infect Dis J. 2015 Sep;34(9):e222-32
pubmed: 26376316
Clin Infect Dis. 1995 Nov;21(5):1211-9
pubmed: 8589145
Clin Vaccine Immunol. 2014 Dec;21(12):1613-9
pubmed: 25253666
Anal Biochem. 1986 Jul;156(1):220-2
pubmed: 3740412
Pediatrics. 1995 Sep;96(3 Pt 2):548-57
pubmed: 7659475
Clin Chem. 1999 Jun;45(6 Pt 1):869-81
pubmed: 10351997

Auteurs

Gowrisankar Rajam (G)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA. Electronic address: gowrisankar.rajam@merck.com.

George Carlone (G)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Ellie Kim (E)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Jin Choi (J)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Simon Paulos (S)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

SoHee Park (S)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Amilia Jeyachandran (A)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Yamini Gorantla (Y)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Emily Wong (E)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Amit Sabnis (A)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Peter Browning (P)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Rita Desai (R)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Conrad P Quinn (CP)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Jarad Schiffer (J)

Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antibactériens › Development and validation of a robust...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes bactériens › Development and validation of a robust...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de la membrane externe bactérienne › Development and validation of a robust...
questionsmedicales.fr › Bactéries › Proteobacteria › Betaproteobacteria › Burkholderiales › Alcaligenaceae › Bordetella › Bordetella pertussis › Development and validation of a robust...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Development and validation of a robust...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Facteurs de virulence › Facteurs de virulence des Bordetella › Toxine pertussique › Development and validation of a robust...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Reproductibilité des résultats › Development and validation of a robust...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Tests sérologiques › Development and validation of a robust...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Facteurs de virulence › Facteurs de virulence des Bordetella › Development and validation of a robust...